Barclays raised the firm’s price target on Guardant Health (GH) to $85 from $70 and keeps an Overweight rating on the shares following the earnings report. Guardant is “firing on all cylinders,” with a broad-based beat across oncology, biopharma and screening, the analyst tells investors in a research note. The firm sees “plenty of opportunities” for the company’s growth trajectory to continue into 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health Reports Strong Q3 2025 Growth
- Guardant Health: Strong Performance and Growth Potential Drive Buy Rating
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings
- Guardant Health reports Q3 EPS (39c), consensus (49c)
- Guardant Health raises FY25 revenue view to $965M-$970M from $915M-$925M